Metropolis Healthcare Limited — PPTs, 07-08-2025: Investor Presentation

Here's a summary of the attached investor presentation:

**1. Financial Highlights:**

Metropolis Healthcare's Q1FY26 Group revenue surged 23% YoY to INR 386 Cr. EBITDA rose 14% to INR 89 Cr (23.1% margin), with PAT up 19%. Organic revenue grew 13% to INR 355 Cr (24.7% EBITDA margin). Patient and test volumes increased significantly, indicating strong operational performance. Acquisitions are positively impacting overall growth.

**2. Strategic Initiatives & Growth Drivers:**

The "Metropolis 3.0" strategy focuses on strengthening core diagnostics, expanding into adjacencies (radiology, primary care), and integrating acquisitions. Growth is fueled by scientific upselling, micro-market focus, and AI-powered digital transformation. Network expanded with new labs and centers, extending reach.

**3. Business Developments:**

Recent acquisitions, like Core Diagnostics turning EBITDA positive, significantly bolstered performance. B2C revenue jumped 19% YoY, and B2B soared 29%. High-value TruHealth and Specialty tests also saw strong growth, supported by new AI-based offerings and clinician engagement.

**4. Market Position & Competitive Advantage:**

With over 43 years of experience and a vast network, Metropolis leverages scientific innovation, AI-driven diagnostics, and a commitment to high quality. Diversified revenue across geographies and increased penetration in Tier II/III cities enhance its competitive edge.

**5. Investor Implications:**

Strong Q1FY26 results, driven by organic momentum and strategic M&A, signal positive growth potential. Focus on high-margin specialized tests and digital advancements could boost profitability. Execution of the "Metropolis 3.0" strategy and acquisition integration remain key to monitor.